medigraphic.com
Colegio de Medicina Interna de México.

2007, Número 1

<< Anterior Siguiente >>

Med Int Mex 2007; 23 (1)


Calidad de vida en pacientes con enfermedad de Parkinson y estimulación cerebral profunda

Pla CCF, García S, Zárate MA, Hernández SM, Sauri SS, Meza DE, Gil OC, Baltasar VJ, Valencia GFJ, Hernández CJ, Meneses LO, González VA, Varela BJ, Menchaca SA, Sosa A, Plascencia ANI, Otero CE, Juárez CJ

Idioma: Español
Referencias bibliográficas: 47
Paginas: 7-14
Archivo PDF: 146.51 Kb.


RESUMEN

Antecedentes: el curso crónico y progresivo de la enfermedad de Parkinson afecta de manera importante la funcionalidad del paciente en la esfera motora, funciones autonómicas y cognitivas. Estos pacientes se vuelven dependientes y generan altos costos familiares, sociales y económicos, entre otros, además de repercutir de manera desfavorable en la calidad de vida.
Objetivo: determinar el efecto de un neuroestimulador cerebral profundo en la calidad de vida de los pacientes con enfermedad de Parkinson.
Pacientes y métodos: se realizó un estudio longitudinal, prospectivo, descriptivo y abierto en el que se evaluó la calidad de vida de los pacientes antes y después de la colocación de un neuroestimulador cerebral profundo.
Resultados: se estudiaron 15 pacientes que tuvieron resultados estadísticamente significativos en las pruebas de Hoehn y Yahr, Schwab & England, UPORS Motor y en la calidad de vida.
Conclusión: el neuroestimulador cerebral profundo mejora la calidad de vida en pacientes con enfermedad avanzada de Parkinson.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Morens DAM, Davis JW, Grandinetii A, Rooss GW, et al. Epidemiologic observations on Parkinson’s disease: incidence and mortality: a prospective study of middle-aged men. Neurology 1996;46:1044-50.

  2. Lauis ED, Marder K, Cote I, Tang M, Mayeux R. Mortality from Parkinson’s disease. Arch Neurol 1997;54:260-4.

  3. Trujillo Z, Rodríguez Y, Corona T, Hernández J, et al. Enfermedad de Parkinson: una guía para el paciente, la familia y el médico. INN y N “MVS”, México, 1995.

  4. Lang AE, Lozano AM. Parkinson’s disease (first of two parts). N Engl J Med 1998;339:1044-53.

  5. DeLong MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosc 1990;13:281-5.

  6. Dierssen G, Gioino G. Correlación anatómica del hemibalismo. Rev Clín Esp 1961;82:283-305.

  7. Hawker R. A large randomised assessment of the relative cost-effectiveness of different classes of drugs for Parkinson’s disease. PD MED Protocol Version 6 March 2003.

  8. Hamada I, DeLong MR. Excitotoxic acid lesions of the primate subthalamic nucleus result in transient dyskinesias of the contralaterallimbs. J Neurophysiol 1992;68:1850-8.

  9. Bergman H, Wichmann T, DeLong MR. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 1990;249:1436-8.

  10. Parent A, Cicchetti F. The current model of basal ganglia organization under scrutiny. Mov Disord 1998;13:199-202.

  11. Lang AE, Lozano AM. Parkinson’s disease (second of two parts). N Engl J Med 1998;339:1130-43.

  12. Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson’s disease? J Neurol Neurosurg Psychiatry 2000;69:308-12.

  13. Benabid AL, Pollack P, Gao DM, Hoffmann D, et al. Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders. J Neurosurg 1996;84:203-14.

  14. Benabid AL, Pollack P, Gervason G, Hoffmann D, et al. Long term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus. Lancet 1991;337:403-6.

  15. Caparros-Lefebvre D, Blond S, Vermersch P, et al. Chronic thalamic stimulation improves tremor and levodopa induced dyskinesias in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1993:56:268-73.

  16. Gálvez Jiménez N, Lozano AE, Tasker R, Duff J, et al. Pallidal stimulation in Parkinson’s disease patients with a prior unilateral pallidotomy. Can J Neurol Sci 1998;25:300-5.

  17. The deep-brain stimulation for Parkinson’s disease study group. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson’s disease. N Engl J Med 2001;345:956-63.

  18. Limousin P, Krack P, Pollak P, Benazzous A, et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson’s disease. N Engl J Med 1998;339:1105-11.

  19. Krack P, Batir A, Van Blercom N, Chabardes S, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson’s disease. N Engl J Med 2003;349:1925-34.

  20. Günther Deuschl, et al. A randomized trial of deep-brain stimulation for Parkinson’s disease. N Engl J Med 2006;355(9):896-908.

  21. Limousin P, Pollak P, Benazzouz A, Hoffmann D, et al. Effect on parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet 1995;345:91-5.

  22. Tomaszewski KJ, Holloway RG. Deep brain stimulation in the treatment of Parkinson’s disease: a cost-effectiveness analysis. Neurology 2001;57:663-71.

  23. Saint Cyr JA, Trepanier LL, Lang AE, Lozano AM. Neuropsychological outcome of posteroventral pallidotomy in parkinsonian patients. Mov Disord 1996;11:161.

  24. Velarde-Jurado E, Avila-Figueroa C. Evaluación de la calidad de vida. Salud Publica Mex 2002;44(4):341-61.

  25. Martinez Martin P, Frades B, Jiménez Jimenez FJ, Condal M, et al. The POQ-39 Spanish version: reliability and correlation with the short-form health survey (SF-36). Neurología 1999;14(4):159-63.

  26. Peto V, Jenkinson C, Fitzpatrick R, Greengall R. The development and validation of a short measure of functioning and well being for individuals with Parkinson’s disease. Qual Life Res 1995:4:241-8.

  27. Jenkinson C, Peto V, Fitzpatrick R, Greenhall R, Hyman N. Selfreported functioning and well-being in patients with Parkinson’ disease: comparison of the short-form health survey (SF-36) and the Parkinson’ and the Parkinson’ disease questionnaire (PDQ-39). Age Ageing 1995;24:505-9.

  28. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36) (I). Conceptual framework and item selection. Med Care 1992:30:473-83.

  29. Ware JE. SF-36 health survey update. Spine 2000;25:3130-9.

  30. Garratt A, Schmidt L, Mackintosh A, Fitzpatrick R. Quality of life measurement: bibliographic study of patient assessed health outcome measures. BMJ 2002:324:1417.

  31. Vilagut G, Ferrer M, Rajmil L, Rebollo P, et. al. El Cuestionario de Salud SF-36 español: una década de experiencia y nuevos desarrollos. Gac Sanit 2005;19(2):135-50.

  32. Fitzpatrick R, Peto V, Jenkinson C, Greenhall R, Hyman N. Health-related quality of life in Parkinson’s disease: a study of outpatient clinic attenders. Mov Disord 1997;12:916-22.

  33. Martinez-Martin P, Frades Payo B. Quality of life in Parkinson’s disease: validation study of the PDQ-39 Spanish version. The Grupo Centro for Study of Movement Disorders. J Neurol 1998; 245 (Suppl 1):S34-S38.

  34. Ware JE Jr, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey: manual and interpretation guide. Boston: New England Medical Center. 1993.

  35. Garratt A, Schmidt L, Mackintosh A, Fitzpatrick R. Quality of life measurement: bibliographic study of patient assessed health outcome measures. BMJ. 2002:324:1417.

  36. Weaver F, Follett K, Hur K, Ippolito, D, Stern M. Deep brain stimulation in Parkinson disease: a metaanalysis of patient outcomes. J Neurosurg 2005;103: 956-67.

  37. Rodriguez-Oroz MC, Obeso JA, Houeto JL, Lang AE, et al. Bilateral deep brain stimulation in Parkinson’s disease: a multicentre study with 4 years follow-up. Brain 2005;128:2240-9.

  38. Saint-Cyr JA, Trepanier LL, Kumar R, Lozano AM, Lang AE. Neuropsychological consequences of chronic bilateral stimulation of the subthalamic nucleus in Parkinson’s disease. Brain 2000:123:2091-108.

  39. Ardouin C, Pillon B, Peiffer E, Bejjani P, et al. Bilateral subthalamic or pallidal stimulation for Parkinson’s disease affects neither memory nor executive functions: a consecutive series of 62 patients. Ann Neurol 1999;46:217-23.

  40. Berney A, Vingerhoets F, Perrin A, Geux P, et al. Effect on mood of subthalamic DBS for Parkinson’s disease: a consecutive series of 24 patients. Neurology 2002;59:1427-9.

  41. Houeto JL, Mesnage V, Mallet L, Pillon B, et al. Behavioural disorders, Parkinson’s disease and subthalamic stimulation. J Neurol Neurosurg Psychiatry 2002;72:701-7.

  42. Global Parkinson’s Disease Survey Steering Committee, Factors impacting on quality of life in Parkinson’s disease’ results from an international survey. Mov Disord 2002;17:60-7.

  43. Hariz M, Johansson F, Shamsgovara P, Johansson E, et al. Bilateral subthalamic nucleus stimulation in a parkinsonian patient with preoperative deficits in speech and cognition: persistent improvement in mobility but increased dependency: a case study. Mov Disord 2000;15:136-9.

  44. Escamilla-Sevilla A, Minguez-Castellanos F, Katati MJ, Martín- Linares JM, et al. Clinical utility of deep brain stimutility in an advenced Parkinson's disease. Neurología 2004;19(10):719-27.

  45. Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson’s disease? J Neurol Neurosurg Psychiatry 2000;69:308-12.

  46. The Global Parkinson’s Disease Survey Steering Committee. Factors impacting on quality of life in Parkinson’s disease: results from an international survey. Mov Disord 2002;17:60-7.

  47. Lagrange E, Krack P, Moro E, Ardouin C, et al. Bilateral subthalamic nucleus stimulation improves health-related quality of life in PD. Neurology 2002;59:1976-78.




2020     |     www.medigraphic.com